163 related articles for article (PubMed ID: 16491322)
1. 2MD, a new anabolic agent for osteoporosis treatment.
Plum LA; Fitzpatrick LA; Ma X; Binkley NC; Zella JB; Clagett-Dame M; DeLuca HF
Osteoporos Int; 2006; 17(5):704-15. PubMed ID: 16491322
[TBL] [Abstract][Full Text] [Related]
2. A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia.
Ke HZ; Qi H; Crawford DT; Simmons HA; Xu G; Li M; Plum L; Clagett-Dame M; DeLuca HF; Thompson DD; Brown TA
J Bone Miner Res; 2005 Oct; 20(10):1742-55. PubMed ID: 16160732
[TBL] [Abstract][Full Text] [Related]
3. A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation.
Shevde NK; Plum LA; Clagett-Dame M; Yamamoto H; Pike JW; DeLuca HF
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13487-91. PubMed ID: 12374862
[TBL] [Abstract][Full Text] [Related]
4. The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial.
DeLuca HF; Bedale W; Binkley N; Gallagher JC; Bolognese M; Peacock M; Aloia J; Clagett-Dame M; Plum L
J Bone Miner Res; 2011 Mar; 26(3):538-45. PubMed ID: 20890933
[TBL] [Abstract][Full Text] [Related]
5. New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro.
Sato M; Nakamichi Y; Nakamura M; Sato N; Ninomiya T; Muto A; Nakamura H; Ozawa H; Iwasaki Y; Kobayashi E; Shimizu M; DeLuca HF; Takahashi N; Udagawa N
Bone; 2007 Feb; 40(2):293-304. PubMed ID: 17070129
[TBL] [Abstract][Full Text] [Related]
6. Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone.
Saito H; Takeda S; Amizuka N
J Steroid Biochem Mol Biol; 2013 Jul; 136():178-82. PubMed ID: 23069645
[TBL] [Abstract][Full Text] [Related]
7. The development of a bone- and parathyroid-specific analog of vitamin D: 2-methylene-19-Nor-(20S)-1α,25-dihydroxyvitamin D3.
Deluca HF
Bonekey Rep; 2014; 3():514. PubMed ID: 24818006
[TBL] [Abstract][Full Text] [Related]
8. Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women.
Zella JB; Plum LA; Plowchalk DR; Potochoiba M; Clagett-Dame M; DeLuca HF
Am J Nephrol; 2014; 39(6):476-83. PubMed ID: 24854296
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of the 2-alkyl and 2-alkylidene-19-nor-(20S)-modified analogs of 1alpha,25-dihydroxyvitamin D3.
DeLuca HF
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):67-73. PubMed ID: 15225749
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of 1alpha,25-dihydroxyvitamin D3 and calcium in osteopenic ovariectomized rats: evidence for a direct anabolic effect of 1alpha,25-dihydroxyvitamin D3 on bone.
Erben RG; Bromm S; Stangassinger M
Endocrinology; 1998 Oct; 139(10):4319-28. PubMed ID: 9751515
[TBL] [Abstract][Full Text] [Related]
11. A New 1,25 Dihydroxy Vitamin D Analog with Strong Bone Anabolic Activity in OVX Rats with Little or no Bone Resorptive Activity.
Plum LA; Zella J; Clagett-Dame M; DeLuca HF
J Bone Miner Res; 2020 Apr; 35(4):623-630. PubMed ID: 31369169
[TBL] [Abstract][Full Text] [Related]
12. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K
J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941
[TBL] [Abstract][Full Text] [Related]
13. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
Weber K; Goldberg M; Stangassinger M; Erben RG
J Bone Miner Res; 2001 Apr; 16(4):639-51. PubMed ID: 11315991
[TBL] [Abstract][Full Text] [Related]
14. Methyl substitution of the 25-hydroxy group on 2-methylene-19-nor-1alpha,25-dihydroxyvitamin D3 (2MD) reduces potency but allows bone selectivity.
Grzywacz P; Plum LA; Sicinski RR; Clagett-Dame M; DeLuca HF
Arch Biochem Biophys; 2007 Apr; 460(2):274-84. PubMed ID: 17094936
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic agents for disorders of bone and calcium metabolism: ED-71].
Tsuji N; Takahashi F
Clin Calcium; 2007 Jan; 17(1):72-9. PubMed ID: 17211096
[TBL] [Abstract][Full Text] [Related]
16. Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089).
Narayanan R; Allen MR; Gaddy D; Bloomfield SA; Smith CL; Weigel NL
Bone; 2004 Jul; 35(1):134-43. PubMed ID: 15207749
[TBL] [Abstract][Full Text] [Related]
17. Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats.
Yao W; Tian XY; Chen J; Setterberg RB; Lundy MW; Chmielzwski P; Froman CA; Jee WS
J Musculoskelet Neuronal Interact; 2007; 7(2):119-30. PubMed ID: 17627081
[TBL] [Abstract][Full Text] [Related]
18. Removal of the 20-methyl group from 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) (2MD) selectively eliminates bone calcium mobilization activity.
Barycki R; Sicinski RR; Plum LA; Grzywacz P; Clagett-Dame M; Deluca HF
Bioorg Med Chem; 2009 Nov; 17(22):7658-69. PubMed ID: 19819702
[TBL] [Abstract][Full Text] [Related]
19. Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.
Iwaniec UT; Mosekilde L; Mitova-Caneva NG; Thomsen JS; Wronski TJ
Endocrinology; 2002 Jul; 143(7):2515-26. PubMed ID: 12072383
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D3 analogs for the treatment of osteoporosis.
Hagino H
Can J Physiol Pharmacol; 2015 May; 93(5):327-32. PubMed ID: 25853632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
